Best overall response to obinutuzumab in the 20 patients who were evaluable radiographically after induction alone or induction and maintenance, compared with pretreatment baseline. Responses were assessed as per the International Working Group criteria/National Cancer Institute criteria in addition to radiologic assessment. Duration of response was defined as the time from when a CR or PR was first recorded to the date of death, the date on which PD was first noted, or the last tumor assessment in patients who did not have PD. The plus (+) sign reflects patients with ongoing responses at the time of the analysis who are continuing to receive follow-up assessment. One patient with DLBCL died of PD before radiologic assessment but was assessed as PD. One patient with CLL discontinued therapy during infusion 1 because of a grade 4 IRR and was not evaluable for response. One patient had a reduction of more than 50% in the sum of product diameters but was assessed as having stable disease by the investigator. FcγRIIIa receptor polymorphisms shown at amino acid residue 158 (F, phenylalanine; V, valine). TL indicates transformed lymphoma; and SPD, sum of product diameters.